Which peptides are gaining traction in the community right now?

The short answer

Seven of the ten fastest-growing peptides in our data are the exact compounds an FDA advisory committee voted on in July 2026. BPC-157 discussion rose 150% and Epitalon 143%, while the GLP-1s fell sharply — tirzepatide down 34%, semaglutide down 30%. This is a regulatory news cycle, not organic discovery.

Evidence tier: Tier 3 — our own analysis of 1,992 classified public posts across Reddit and X, 6 June to 7 August 2026. Mention volume measures attention, not adoption, safety or efficacy. Educational content, not medical advice.

The key points:

• BPC-157 (+150%), Epitalon (+143%), TB-500 (+93%), KPV (+89%) lead the risers — all on the 503A ballot.
• The GLP-1s are down across the board, including retatrutide.
• DSIP rose 82% despite being the one compound the panel rejected.
• Highest sentiment sits with compounds nobody is talking about more — MOTS-c, tesamorelin, CJC-1295/Ipamorelin.
• Two months of data with one large news event in it. Treat as a snapshot, not a trend line.

What we measured

Evidence tier: 3 — methodology.

We analysed 1,992 classified public posts — Reddit and X combined — spanning 6 June to 7 August 2026. Each post is tagged by peptide, topic cluster (experience, dosing, side-effect, vendor, regulatory, research, question) and sentiment.

To find what is gaining rather than what is merely large, we compared mentions in the most recent 30 days against the preceding 30 days, restricted to compounds with at least 12 total mentions so small numbers cannot manufacture a large percentage.

Two honest limits before the numbers. Our ingestion began in June, so there is no meaningful third month to compare against — this is one 30-day window against another, not an established trend. And Reddit engagement counts are not captured in our pipeline, so this measures how often something is discussed, not how much attention each post received.

Which peptides are gaining traction?

Evidence tier: 3 — our data.

• **BPC-157 — Recent 30d: 135 · Prior 30d: 54 · Change: +150%** · Sentiment: +0.24
• **Epitalon — Recent 30d: 56 · Prior 30d: 23 · Change: +143%** · Sentiment: +0.26
• 5-Amino-1MQ — Recent 30d: 12 · Prior 30d: 6 · Change: +100% · Sentiment: +0.17
• **TB-500 — Recent 30d: 56 · Prior 30d: 29 · Change: +93%** · Sentiment: +0.28
• **KPV — Recent 30d: 83 · Prior 30d: 44 · Change: +89%** · Sentiment: +0.17
• **DSIP — Recent 30d: 31 · Prior 30d: 17 · Change: +82%** · Sentiment: +0.28
• Cerebrolysin — Recent 30d: 24 · Prior 30d: 17 · Change: +41% · Sentiment: +0.18
• Oxytocin — Recent 30d: 8 · Prior 30d: 7 · Change: +14% · Sentiment: +0.22
• Semax — Recent 30d: 66 · Prior 30d: 60 · Change: +10% · Sentiment: +0.33
• MOTS-c — Recent 30d: 91 · Prior 30d: 84 · Change: +8% · Sentiment: +0.37

And the other direction:

• Sermorelin — Recent 30d: 7 · Prior 30d: 14 · Change: −50% · Sentiment: +0.35
• **Tirzepatide — Recent 30d: 201 · Prior 30d: 305 · Change: −34%** · Sentiment: +0.21
• **Semaglutide — Recent 30d: 99 · Prior 30d: 142 · Change: −30%** · Sentiment: +0.18
• CJC-1295 / Ipamorelin — Recent 30d: 40 · Prior 30d: 53 · Change: −25% · Sentiment: +0.37
• GHK-Cu — Recent 30d: 79 · Prior 30d: 103 · Change: −23% · Sentiment: +0.24
• Tesamorelin — Recent 30d: 47 · Prior 30d: 58 · Change: −19% · Sentiment: +0.37
• Retatrutide — Recent 30d: 123 · Prior 30d: 142 · Change: −13% · Sentiment: +0.31
• Selank — Recent 30d: 35 · Prior 30d: 37 · Change: −5% · Sentiment: +0.28

Why is BPC-157 suddenly up 150%?

Evidence tier: 2 — regulatory event, directly observable.

Because of a vote, not a discovery.

In July 2026 an FDA advisory committee considered a set of peptides for the 503A bulks list — the list determining what compounding pharmacies may legally prepare. The compounds it recommended were BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV. It rejected DSIP.

Now compare that list to the risers table. Seven of the top ten fastest-growing compounds are on that ballot.

The other three did not rise for a shared reason, and reading each one individually is instructive — because none of them rose because of growing interest either.

5-Amino-1MQ (+100%) rose on a contamination incident. All twelve recent mentions are on X, none on Reddit, and they trace a single testing saga: a sample screening positive for fentanyl, competing theories about whether iodide caused a false positive, retests at multiple labs, and eventual negative confirmations. A third of the posts are vendor-cluster, some of them straightforward promotions running alongside the story. This is a product-safety event plus marketing, on one platform, driven by a handful of accounts.

Cerebrolysin (+41%) rose on sourcing friction. Nineteen of its 24 recent mentions are on Reddit, 16 of those inside a dedicated subreddit, and the dominant question is simply how to obtain it: from India, from the UK, from Canada, whether it can be had in the US at all, and whether a given supplier is selling a counterfeit. Cerebrolysin is not approved in the US or UK, so the conversation is about access rather than effect.

Oxytocin (+14%) is noise — one additional post, and two of the eight tagged it only incidentally within multi-compound stack posts.

So the honest summary is stronger than "seven of ten." None of the ten fastest-growing compounds rose because people newly decided they were interesting. Seven rose on a regulatory vote, one on a contamination scare, one on supply problems, and one is a rounding error.

This matters for how you read "trending." Nothing changed about BPC-157's evidence base in July. No trial reported, no new mechanism, no safety finding. What changed was its legal availability in the United States, and attention followed the legal question rather than the scientific one.

It is worth being clear that the vote itself was narrower than the coverage suggested: BPC-157 and TB-500 both passed 8–6 with one abstention, and a recommendation is not FDA approval. The surge in discussion is running well ahead of what was actually decided.

What does the GLP-1 decline mean?

Evidence tier: 3 — our data, with caveats.

Every GLP-1 in the dataset fell: tirzepatide −34%, semaglutide −30%, retatrutide −13%.

The tempting reading is that people are moving on. We do not think that is right, and the numbers argue against it. Tirzepatide is still the most-discussed compound in the corpus by a wide margin at 201 recent mentions — more than BPC-157's 135 even after BPC-157's 150% surge. Retatrutide sits third at 123.

A more plausible explanation is that attention is finite and a news event pulled it elsewhere. GLP-1 discussion is also maturing: these drugs have been in mainstream use long enough that the novelty phase has passed, and much of the conversation has migrated to condition-specific communities rather than general peptide forums, where our pipeline is weighted.

The sentiment data supports the "maturing, not abandoned" reading. Semaglutide sits at +0.18 and tirzepatide +0.21 — the lowest of any well-discussed compound, but stable, and consistent with a population past the honeymoon and dealing with plateaus, side effects and cost. Retatrutide's higher +0.31 is what an earlier point on that same curve looks like.

Which compound is the anomaly?

Evidence tier: 3 — our data.

DSIP, and it is the most interesting number in the dataset.

DSIP is the one compound the advisory committee rejected. It nonetheless rose 82%, with a sentiment of +0.28 — higher than BPC-157's. Discussion of a peptide increased sharply immediately after a regulatory body declined to endorse it.

Two explanations seem plausible, and we cannot distinguish them from this data. The first is scarcity: a rejection signals restricted future availability, which reliably drives interest and stockpiling behaviour. The second is simpler — DSIP was named in every article and thread covering the vote, so it received the same attention as the compounds that passed, and most people reading did not register which side of the line it fell on.

Either way, the practical implication is the same. Being discussed more is not evidence of being endorsed more. For DSIP specifically, the direction of the regulatory finding and the direction of the conversation point opposite ways.

What does sentiment show that volume doesn't?

Evidence tier: 3 — our data.

The two measures disagree, and the disagreement is informative.

The highest-sentiment compounds are not the ones gaining attention. MOTS-c (+0.37), tesamorelin (+0.37) and CJC-1295/Ipamorelin (+0.37) top the sentiment table, and only MOTS-c is growing at all — tesamorelin is down 19% and CJC/Ipamorelin down 25%. These are compounds people who use them speak well of, discussed by a shrinking share of the conversation.

Meanwhile KPV grew 89% on the lowest sentiment of any riser (+0.17) — a lot of new discussion, noticeably less enthusiasm than the compounds it was voted alongside. That is what a compound looks like when attention arrives before experience does.

The general lesson: volume tracks news, sentiment tracks use. If you want to know what is in the headlines, read the growth column. If you want to know what people who actually take something think of it, read the sentiment column. They are answering different questions, and this month they disagree sharply.

Limitations

This is educational content, not medical advice, and none of it is evidence about whether any compound works.

• Mention volume is not adoption, efficacy or safety. A peptide can trend because of a legal ruling, a viral post, or a scandal.
• Two months of data with one major news event inside it. The 503A vote dominates the window; a comparison across a quieter period would look different.
• Reddit engagement is not captured in our pipeline, so this counts posts, not attention per post.
• Posters are self-selected, skewing toward people with something to report and toward the communities our sources cover.
• Sentiment is machine-classified and missing on a substantial share of Reddit posts, so those averages rest on a subset.
• Small-n compounds — 5-Amino-1MQ, Oxytocin — move large percentages on a handful of posts and should not be read as trends.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

The honest answer to "what peptides are gaining traction" is that a regulatory committee published a list, and the conversation reorganised itself around that list within weeks. BPC-157, Epitalon, TB-500 and KPV are not up because anything was learned about them. They are up because their legal status in the United States may be about to change, on a vote that was narrower — 8–6 on BPC-157 — than almost any coverage conveyed.

The GLP-1s falling 30% is not a collapse in interest. Tirzepatide remains the single most-discussed compound in the corpus. It is what a maturing category looks like when a louder story arrives next door.

The number worth sitting with is DSIP: up 82%, and the only compound the panel turned down. Attention and endorsement moved in opposite directions, which is a reasonable summary of this entire dataset. If you are using discussion volume as a proxy for whether something is worth taking, this month is a clean demonstration of why that does not work.

Related on this site

• Live community signal feed
• State of the peptide community 2026
• Why most longevity peptide stacks don't survive evidence scrutiny
• Pinealon and Epitalon for sleep: what Huberman actually said
• Peptide myths debunked: what's hype and what's real
• Our evidence-tier framework

References

• My Peptide Story community signal pipeline — 1,992 classified public posts from Reddit and X, 6 June to 7 August 2026. Methodology described above; data available on request for citation.
• FDA advisory committee (PCAC) 503A bulks list recommendations, July 2026 — BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV recommended; DSIP rejected. BPC-157 and TB-500 each passed 8–6 with one abstention.